Company research
Anthera Pharmaceuticals Inc
CIK 1316175Updated Nov 16, 2026
SecurityANTH · OTC · equity
ANTH price & chart
Loading TradingView…
OTC:ANTH on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2017 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,673,000Source | 23,471,000Source | 48,125,000Source | 3,490,000Source |
| Property, Plant and Equipment, NetUSD | 482,000Source | 763,000Source | 263,000Source | 468,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,196,000Source | 20,843,000Source | 46,951,000Source | 2,639,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 326,000Source | — |
| Assets, CurrentUSD | 3,191,000Source | 22,708,000Source | 47,862,000Source | 3,022,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 995,000Source | 1,865,000Source | 585,000Source | 383,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 9,168,000Source | 10,624,000Source | 8,468,000Source | 5,751,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 14,000Source | 46,000Source | 40,000Source | 23,000Source |
| Retained Earnings (Accumulated Deficit)USD | -434,428,000Source | -407,554,000Source | -352,031,000Source | -316,811,000Source |
| Stockholders' Equity Attributable to ParentUSD | -5,495,000Source | 12,470,000Source | 39,657,000Source | -2,261,000Source |
| Additional Paid in Capital, Common StockUSD | 428,586,000Source | 411,364,000Source | 391,648,000Source | 314,527,000Source |
| Liabilities and EquityUSD | 3,673,000Source | 23,471,000Source | 48,125,000Source | 3,490,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,711,000Source | 10,624,000Source | 8,468,000Source | 5,751,000Source |
| Accounts Payable, CurrentUSD | 1,832,000Source | 4,782,000Source | 5,259,000Source | 2,232,000Source |
| Other Liabilities, NoncurrentUSD | 4,457,000Source | — | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,066,000Source | 113,000Source | 98,000Source | 211,000Source |
| Deferred Revenue, CurrentUSD | — | — | 138,000Source | — |
cash flow · annual statements
| Line item | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,379,000Source | 6,739,000Source | 3,541,000Source | 2,175,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | -326,000Source | 326,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | -2,950,000Source | -477,000Source | 3,027,000Source | -1,210,000Source |
| Deferred Income Tax Expense (Benefit)USD | 28,931,000Source | -12,006,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -36,900,000Source | — | — | — |
| Cash flows from investing activities: | ||||
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 766,000Source | 80,000Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 18,253,000Source | — | — | — |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 1,694,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 4,379,000Source | 6,739,000Source | 3,541,000Source | 2,175,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | 226,000Source |
| DepreciationUSD | 281,000Source | 266,000Source | 285,000Source | 344,000Source |
| General and Administrative ExpenseUSD | 7,938,000Source | 11,071,000Source | 7,568,000Source | 6,620,000Source |
| Net Income (Loss) Attributable to ParentUSD | -26,874,000Source | -55,523,000Source | -35,220,000Source | -29,604,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -29,377,000Source | -66,437,000Source | -35,220,000Source | -29,604,000Source |
| Nonoperating Income (Expense)USD | 9,558,000Source | 1,654,000Source | 23,000Source | — |
| Operating ExpensesUSD | 36,432,000Source | 57,322,000Source | 38,428,000Source | 28,459,000Source |
| Other Nonoperating Income (Expense)USD | -85,000Source | -90,000Source | 23,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | 6,429,000Source | 65,889,000Source | 10,351,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 257,000Source | 299,000Source | 4,000Source |
income statement · annual statements
| Line item | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|
| Total RevenueUSD | — | 145,000Source | 3,185,000Source | — |
| Operating Income (Loss)USD | -36,432,000Source | -57,177,000Source | -35,243,000Source | -28,459,000Source |
| Other Nonoperating Income (Expense)USD | -85,000Source | -90,000Source | 23,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -26,874,000Source | -55,523,000Source | -35,220,000Source | -29,604,000Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 10,278,391Source | 41,310,269Source | 35,631,237Source | 21,776,269Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 1,000Source | 1,000Source | — | — |
| General and Administrative ExpenseUSD | 7,938,000Source | 11,071,000Source | 7,568,000Source | 6,620,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 29,400,000Source | -66,400,000Source | — | — |
| Interest and Other IncomeUSD | — | — | — | -96,000Source |
| Interest ExpenseUSD | — | — | — | 1,049,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -29,377,000Source | -66,437,000Source | -35,220,000Source | -29,604,000Source |
| Nonoperating Income (Expense)USD | 9,558,000Source | 1,654,000Source | 23,000Source | — |
| Operating ExpensesUSD | 36,432,000Source | 57,322,000Source | 38,428,000Source | 28,459,000Source |
| Research and Development ExpenseUSD | 28,594,000Source | 46,512,000Source | 33,498,000Source | 21,839,000Source |